Open AccessRecent advances in the treatment of opioid use disorders–focus on long-acting buprenorphine formulations
Author(s) -
Michael Soyka,
Andreas G. Franke
Publication year - 2021
Publication title -
world journal of psychiatry
Language(s) - English
Resource type - Journals
ISSN - 2220-3206
DOI - 10.5498/wjp.v11.i9.543
Subject(s) - buprenorphine , medicine , opioid , opioid use disorder , narcotic antagonists , pharmacology , naltrexone , intensive care medicine , (+) naloxone , receptor
Oral methadone or sublingual buprenorphine are first-line medications for pharmacotherapy of opioid use disorders (OUDs). Three long-acting buprenorphine depot or implant formulations are currently available for the treatment of OUDs: (1) CAM 2038 (Buvidal) for subcutaneous weekly and monthly application; (2) RBP-6000 (Sublocade™) as a monthly depot formulation; and (3) A six-month buprenorphine implant [Probuphine™]. The pharmacology, clinical efficacy and prospects of these medications are discussed.